Wednesday, March 05, 2025 | 06:45 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Covaxin 77.8% effective against symptomatic Covid-19, says Bharat Biotech

The analysis also found that Covaxin is 93.4 per cent effective against severe symptomatic Covid-19

Bharat Biotech, Covaxin
Premium

Covaxin has an efficacy of 65.2% against the SARS-CoV-2, B.1.617.2 Delta variant

BS Web Team New Delhi
Bharat Biotech on Saturday announced safety and efficacy analysis data from phase III clinical trials of Covaxin. 

The company said the efficacy analysis found that Covaxin is 77.8% effective against symptomatic Covid-19 through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.

The analysis also found that while Covaxin is 93.4 per cent effective against severe symptomatic Covid-19, it demonstrates an efficacy of 63.6% against asymptomatic Covid-19 and an efficacy of 65.2% against the SARS-CoV-2, B.1.617.2 Delta variant.

“The successful safety and efficacy readouts of Covaxin as a result of conducting

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in